{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-218062","form_type":"8-K","ticker":"APLS","cik":"0001492422","company_name":"Apellis Pharmaceuticals, Inc.","filed_at":"2023-08-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.071634+00:00","generated_at":"2026-06-11T05:34:56.396976+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Apellis updates on 8 retinal vasculitis events with SYFOVRE; recommends switching to 18-gauge filter needle","bullets":["Over 100,000 SYFOVRE vials distributed; 8 confirmed retinal vasculitis events (5 occlusive, 3 non-occlusive) as of June 20.","Last confirmed event on June 20; over 32,000 vials distributed since then with no new confirmed events.","One additional occlusive event in May reported after July 29; all events occurred after first injection.","Company recommends discontinuing use of 19-gauge filter needle kits; now exclusively distributing 18-gauge filter needle kits.","Patient outcomes: 1 stable, 2 near baseline, 2 severe vision impairment, 3 pending; two suspected events also reported."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-218062","json":"https://secwatch.observer/filing/0001193125-23-218062.json","markdown":"https://secwatch.observer/filing/0001193125-23-218062.md","text":"https://secwatch.observer/filing/0001193125-23-218062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1492422/000119312523218062/0001193125-23-218062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1492422/000119312523218062/d539134d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T05:34:56.396976+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}